Cargando…
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
BACKGROUND. Monogenic IFN–mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to ameliorate disease. METHODS. Betwe...
Ejemplares similares
-
Monogenic interferonopathy presenting as CMV infection in infancy
por: Schütz, C, et al.
Publicado: (2015) -
Multisystem inflammatory syndrome in children associated with COVID‐19 presenting as cervical inflammation
por: Brooks, Rebecca, et al.
Publicado: (2022) -
Myasthenia Gravis: An Acquired Interferonopathy?
por: Payet, Cloé A., et al.
Publicado: (2022) -
Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies
por: Kim, Hanna, et al.
Publicado: (2020) -
The type I interferonopathies: 10 years on
por: Crow, Yanick J., et al.
Publicado: (2021)